Lyell Immunopharma announced that the FDA granted Orphan Drug Designation to LYL845, an investigational tumor infiltrating lymphocyte, or TIL, product candidate for the treatment of patients with stage IIB-IV melanoma.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LYEL:
- Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
- Lyell Immunopharma price target lowered to $8 from $9 at H.C. Wainwright
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
- Lyell Immunopharma treatment of Stage IIB-IV melanoma granted orphan status
- Lyell Immunopharma is presenting nonclinical data at SITC on LYL119
